

# Management of accessory parotid gland tumours: 32-year experience from a single institution and review of the literature

---

Lukšić, Ivica; Mamić, Matija; Suton, Petar

Source / Izvornik: **International Journal of Oral and Maxillofacial Surgery, 2019, 48, 1145 - 1152**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1016/j.ijom.2019.02.014>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:433801>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2024-10-14**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)



**Management and surgical treatment of accessory parotid gland tumors: 32-year experience  
from a single institution and systematic review of the literature**

**Running Head:** Treatment of accessory parotid gland tumors

Ivica Luksic MD, PhD<sup>1</sup>, Matija Mamic, MD<sup>1</sup>, Petar Suton, MD, PhD<sup>2</sup>

<sup>1</sup>University of Zagreb School of Medicine, University Hospital Dubrava, Department of Maxillofacial Surgery, Avenue Gojko Susak 6, 10000 Zagreb, Croatia

<sup>2</sup>University Hospital Centre "Sisters of Mercy", University Hospital for Tumors, Department of Radiotherapy and Medical Oncology, Ilica 197, 10000 Zagreb, Croatia

***Corresponding Author:***

Prof. Ivica Luksic, MD, MSc, PhD

Department of Maxillofacial Surgery

University Hospital Dubrava

Ave. Gojko Susak 6

10000 Zagreb, Croatia

Phone: +385 1 2903 431

Fax: +385 1 2864 250

E-mail: [luksic@kbd.hr](mailto:luksic@kbd.hr)

**Meeting information:** A part of this manuscript, in a form of an abstract, was accepted for 24<sup>th</sup> European Association for Cranio Maxillo Facial Surgery (EACMFS) Congress, which took place on 18-21 September 2018 in Munich, Germany.

**Key words:** accessory parotid gland tumors, salivary gland tumors, surgical treatment, parotidectomy, facial nerve

## **Abstract**

Accessory parotid gland tumors (APGT) are very rare. Regarding their anatomical location an adequate surgical approach is necessary to provide safe resection and satisfactory postoperative result. Aims of this study were to present our tertiary center experience in surgical treatment and management of APGT and to review the literature regarding their treatment, particular in terms of surgical modalities. Data of thirteen patients with primarily surgically treated APGT have been collected and analyzed. Approaches included standard parotidectomy and facelift incision. Well-documented English-literature articles of surgically treated APGT have been extracted from the PubMed, Scopus and Web of Science databases ending in May 2018 and analyzed. Mean age at the diagnosis was 41.1 years. The most common benign histological subtype was pleomorphic adenoma (53.8%), while mucoepidermoid carcinoma (23.1%) was most common in malignant counterparts. A malignancy rate was 38.5%. Postoperative results were satisfying, and follow-up period was uneventful in all patients except one who died of locoregional recurrence. A total of 57 papers with reported series in APGT have been identified with a total of 306 APGT cases. From oncosurgical, functional and cosmetic standpoints approaches through a standard parotidectomy and facelift incision provide satisfactory results.

## Introduction

The accessory parotid gland is an isolated cluster of salivary tissue which lies between the buccal and zygomatic branches of the facial nerve on the masseter muscle. It occurs typically around the midpoint of an imaginary line drawn from the tragus of the ear to a point halfway between the alae of the nose and the vermilion border of the upper lip.<sup>1</sup> Despite the incidence of accessory parotid gland being reported to be 21-56% among human cadavers<sup>2,3</sup>, tumors originating from accessories are extremely rare and constitute 1-7.7% of all parotid gland tumors.<sup>1,4</sup> The reported malignancy rate of accessory parotid gland tumors (APGT) is higher than tumors in the parotid, ranging from 26 to 50%.<sup>4,5</sup>

The mainstay of treatment of APGT is surgical resection. Surgical treatment includes preservation of anatomical structures related to the affected region, while respecting oncological principles. Preservation of the facial nerve is the most important aspect in surgical treatment. The selection of an optimal approach used in the surgical treatment of APGT is the subject of the discussion. The most frequently utilized include approaches through the standard parotidectomy incision, facelift incision, and direct transcutaneous or transoral incisions. Recent reports presented the minimally invasive endoscopic-assisted surgery as an alternative method in the treatment of APGT.<sup>6-9</sup>

The aims of this study were to present our tertiary center's experience in surgical treatment and management of APGT and to review the literature regarding its diagnostics, work-up and treatment, particular in terms of surgical modalities.

## Materials and methods

### *Patients*

Data were collected retrospectively from the institutional salivary tumors database for the period between 1 January 1985 and 31 December 2016 at the Department of Maxillofacial Surgery, University Hospital Dubrava, Zagreb. Patients with APTG who were primarily surgically treated, were included in the study. Mid-cheek masses other than APTG were excluded from further analysis. The follow-up interval was calculated in months from the date of a first treatment to the date of a last follow-up or death. The follow-up period was concluded on 31 December 2017.

Well-documented English-literature articles of surgically treated APTG have been extracted from the PubMed, Scopus and Web of Science databases ending in May 2018 and analyzed. The search strategy used a key-word “accessory parotid gland tumors”. Search was performed independently by 2 reviewers (M.M., P.S.).

Per the institutional review board of the University Hospital Dubrava, Zagreb, this study met criteria for nonhuman subject research, and as a result, board approval was not required.

### *Treatment*

Pre-operative evaluation included careful physical examination, ultrasound-guided fine-needle aspiration cytology (US-guided FNAC), and multislice computed tomography (MSCT) or magnetic resonance imaging (MRI) (**Figure 1**). After the diagnosis of APTG was established, surgical management was conducted through a standard parotidectomy incision (modified Blair incision) or facelift incision (**Figure 2**). After elevation of the anterior skin flap, initial tracing of the facial nerve main trunk introducing anterograde dissection of its branches was performed

**(Figure 3).** Following identification of the zygomatic and buccal branches, excision of the accessory parotid gland with concurrent superficial parotidectomy was done. Superselective or selective neck dissections were carried out in the cases with preoperative assessed malignant tumor. Postoperative radiation therapy (PORT) was conducted in cases of high-grade tumors or advanced-stage disease. With daily fractions of 2 Gy, a prophylactic dose of 50 Gy to clinically undissected neck levels was given, with a boost of 60 Gy to the tumor bed and metastases confined to lymph nodes. The follow-up protocol consisted of medical history and physical examination every 3, 6, 8, and 12 months, in the first, second, third, and fourth year of follow-up, respectively.

## Results

During the 32-year period, 792 patients with parotid gland tumor were primarily surgically treated at our institution. Accessory parotid gland tumors comprised 1.64% of all surgically treated parotid gland tumors (13/792). Clinical features of the study group are summarized in **Table 1**. Mean age at the diagnosis of APGT was 41.1 (range, 15-70) years. A total of 53.8% (n=7) patients were male and 46.2% (n=6) were female. Mean age of patients with benign tumors was 40 years, while in malignant counterparts it was 43 years. Tumors arising in accessory parotid gland presented a malignancy rate of 38.5% (5/13). The most common benign histological subtype was pleomorphic adenoma (PA) (53.8%), followed by myoepithelioma (7.5%). Among malignant tumors the most common subtype was mucoepidermoid carcinoma (MEC) (23.1%), followed by carcinoma ex-PA (7.5%) and adenoid cystic carcinoma (7.5%). Eleven patients (84.6%) were treated primarily surgically, while two patients (15.4%) were referred to our institution due to local recurrence of PA after previous treatment in other institution (both treated using transcutaneous incision). In 2 cases (15.4%), final pathological diagnosis was non-consistent with preoperative FNAC diagnosis (MEC misdiagnosed as lymphoepithelial cyst and carcinoma ex-PA misdiagnosed as skin adnexal carcinoma). Four patients with malignant disease underwent concurrent neck dissection, two of which were therapeutic. Three patients underwent superselective dissection of region II, while one was treated with selective neck dissection of levels I-III. Twelve accessory parotidectomies entailed a superficial parotid lobectomy, while one entailed a total parotidectomy with composite resection of the masseter muscle (case of high-grade MEC). In 2 patients a lymph node within the superficial parotid lobe was involved by APGT metastasis, while in 11 patients the parotid was tumor-free. One patient with a positive intraparotid lymph node had a positive neck dissection



specimen (case of high-grade MEC). Two patients had a positive neck without involvement of the superficial lobe of the parotid gland, with one dissection being elective. In 4 cases of superficial parotidectomy buccal and/or zygomatic branches were in close relation with the APGT and were sacrificed in order to achieve tumor clearance. Apart from patients in whom peripheral branches were sacrificed, two patients (22.2%) developed transient facial nerve palsy. Four patients with malignant tumors underwent PORT. At the time of follow-up, all patients were disease-free, except one with MEC who developed a locoregional recurrence 8 months after initial treatment and died 6 months later. At 5 years, overall survival was 92.3%. Mean follow-up was 69 months (range 14-220 months).

Extracted data from the literature of surgically treated APGT are summarized in **Table 2**.

## Discussion

Tumors of the accessory parotid gland are rare and the literature usually depends on individual case reports and limited case series. A total of 57 papers with expertise in APGT have been identified with a total of 306 APGT cases.<sup>1-4,6-58</sup> The series of patients presented in this study is an updated report, previously published by the senior author.<sup>10</sup> According to our knowledge, this is the largest European series of APGT treated at a single institution, and the fifth largest published in the English literature overall.<sup>1,4,11,12</sup>

The neoplasms located in accessory parotid tissue usually present as a slow-growing, painless, mid-cheek masses. In most studies, the age of occurrence ranges between 45 and 64 years.<sup>12-15</sup> On the contrary, in our study patients were younger with a mean age of 41 years. In our series, the most frequent histological subtype of benign APGT was pleomorphic adenoma (PA), while the most common malignant subtype was mucoepidermoid carcinoma (MEC). A similar pattern of distribution with respect to histological subtype has been published in the literature<sup>1,4,12</sup>, except for Ma's study in which the most common malignant subtype was lymphoma, followed by lymphoepithelial carcinoma and acinic cell carcinoma.<sup>11</sup>

The incidence of APGT among all parotid tumors primary surgically treated at our institution was 1.64% with a malignancy rate of 38.5% and this is consistent with previous publications.<sup>1,4,11</sup> According to the pooled data extracted from all available studies, the malignancy rate of APGT is 28.8% (88/306). In our study, the 5-year overall survival rate for all patients with APGT was 92.3%, while patients with malignant APGT had a survival rate of 80% in the same time interval. One patient (MEC) developed locoregional recurrence and died due to disease recurrence. While

other series reported a favorable outcome in terms of survival and recurrence among benign tumors, data related to survival of malignant tumors have not been reported.

Pretreatment cytological and radiological findings were the main factors for determining the extent of surgical treatment. In two cases FNAC has not been consistent with definitive patohistological diagnosis presenting preoperative diagnostic sensitivity of 84.6% (two initially benign tumors were later deemed malignant in the definitive histological report). In the first patient (No 11) the diagnosis of MEC on final patohistological report was preoperatively described as a lymphoepithelial cyst, while in second patient (No 12) carcinoma ex-PA was described as a skin adnexal carcinoma (**Table 1**). The FNAC of low-grade MEC is well recognized for its potential false-negative diagnostic pitfall, due to the bland cytological features and hypocellular nature of this histological subtype.<sup>59,60</sup> The differential diagnosis of low-grade MEC includes Warthin tumor, benign salivary gland cysts (lymphoepithelial cysts), branchial cleft cyst, sialolithiasis or chronic sialadenitis complicated by cystic dilatation, and pleomorphic adenoma with excess mucoid stroma.<sup>61,62</sup> Hughes et al. reported that the diagnostic accuracy of FNAC decreased to 48%, with a sensitivity of 73% in detection of malignant and 91% in benign parotid gland tumors.<sup>63</sup> In this study, the benefit of using US-guided FNAC has been demonstrated in patient (No 12) with carcinoma ex-PA in which US-guided FNAC has shown neck metastasis in region II, previously unsuspecting on physical examination and MSCT (**Table 1**). Although in this case FNAC was not consistent with definitive patohistological diagnosis, positive neck lymph node consequently affected planning of the surgery. Given the fact that US-guided FNAC offers additional information regarding enlarged lymph nodes and malignancy in small lymph nodes not identified by other methods, it can be recommended as part of preoperative work-up for most salivary gland tumors, which is supported by the literature.<sup>64-66</sup>

The mainstay of treatment for APGT is surgical excision. However, selection of an optimal approach and the extent of treatment is the subject of debate. Except for one case (No 1), in all other cases concurrent superficial parotidectomy was entailed (**Table 1**). Although it is unnecessary for the management of benign APGT, it was performed to allow better access to APGT. Moreover, considering preoperative inconsistency with definitive pathological report, superficial parotidectomy may provide an extra margin in oncological terms. The optimal surgical approach should provide safe access to the tumor, flexibility, and easy manipulation. Also, of significant importance is a satisfying aesthetic result. The treatment procedures reported in the literature consisted of traditional surgery (90.8%) and endoscopic-assisted surgical techniques (9.2%) (**Table 2**). Approaches used in both of these procedures were external (transcutaneous) and transoral. The discrepancy between the total number of APGT (n=305) and the total number of reported approaches (n=261) in **Table 2** stems from the lack of information with respect to treatment modalities in published articles.

Surgical approaches used in the present study were the standard parotidectomy incision (61.5%) and facelift incision (38.5%) (**Figure 2**). Both approaches provide optimal visibility of APGT and surrounding structures (**Figure 3**). Wide operative field allows flexibility and safe dissection of the facial nerve trunk with tracing of all its branches and parotid duct. Postoperatively, apart from 4 patients in whom the buccal branches were sacrificed in order to achieve macroscopic tumor clearance, only 2 (15.4%) patients developed transitory facial nerve palsy. No case of salivary fistula or gustatory sweating syndrome was noted. The postoperative scars were hidden in the cervical crease and hair-bearing portion of the scalp providing a satisfying aesthetic result in all patients (**Figure 4**). The facelift approach is considered as a gold standard in facial rejuvenation, so from the aesthetic standpoint, its utilization in oncosurgery is highly acceptable. Interestingly,

the very low rate (2.1%) of facelift incisions according to the reviewed literature has been reported (**Table 2**). Possible reason could be inexperience in the treatment of such a rare tumor through a generally considered aesthetic approach. The preference of using an approach through standard parotidectomy incision was reported by Perzik and White, presenting 20 patients without facial nerve injury and good aesthetic results.<sup>1</sup> Other authors reported similar outcome.<sup>15-18</sup> Both standard parotidectomy and facelift approaches permit frozen sectioning and easy conversion into neck dissection if necessary. These approaches are also appropriate in clinically positive lymph node settings.

The direct approach through transcutaneous mid-cheek incision reduces the damage of the surrounding tissue and shortens the duration of treatment. In our opinion, this approach should be reserved for experienced surgeons, due to high risk of injury of facial nerve.<sup>4</sup> The chance of damaging peripheral branches and Stensen's duct may be increased up to 40%, as reported.<sup>4</sup> Other potential complications include seeding of the tumor, development of a salivary fistula and local recurrence.<sup>4,13</sup>

The main advantages of the direct transoral approach are no visible scars and time-saving compared to the standard parotidectomy incision.<sup>14,19-21</sup> However, it is limited to cases of small-sized tumors located more anteriorly, which reduces the risk of Stensen's duct or facial nerve impairment.<sup>14</sup> Its disadvantage is reduced operative viewing field implicating difficulties in manipulation and bleeding control.<sup>13,17</sup> For these reasons, the direct transoral approach has been described as "ill-advised".<sup>17</sup> Some authors used a nerve monitor to identify small nerve branches.<sup>21,22</sup> Even though the monitor indicate near the nerve, it does not guarantee visualization, and is therefore a routine visualization recommended.<sup>22</sup>

In recent years, endoscopic-assisted surgery has become more frequent in the head and neck. There are few reports on endoscopic assisted treatment of APGT.<sup>6-9</sup> Xie et al. first described such a technique in a series of 5 patients via a 4-5cm preauricular incision and assistance of working space-maker.<sup>6</sup> Li et al. modified the previously mentioned approach with shorter and less visible skin incisions.<sup>7</sup> However, in all series of transcutaneous endoscopic procedures, only benign APGT less than 3.2 cm in size were included.<sup>6-8</sup> To date, only one case of transoral endoscopic-assisted resection of APGT has been described.<sup>9</sup> The advantages of endoscopic-assisted surgery over traditional surgery include reduced tissue damage, low incidence of wound-related complications and minimal scarring. The endoscope provides sufficient illumination and magnification of the operative field.<sup>6,8</sup> Postoperatively, no case of facial nerve palsy, infection, salivary fistula, gustatory sweating syndrome or local recurrence has been noted, all reporting satisfactory cosmetic result.<sup>6-9</sup> The follow-up periods varied between 2 and 14 months. On the contrary, disadvantages of endoscopic-assisted surgery are inability to operate large and malignant tumors, reservation for trained professionals in endoscopic techniques and a time-consuming procedure which is difficult to compare with traditional surgery due a small case series.<sup>6-8</sup> Furthermore, discrepancies between preoperative FNAC and definitive patohistological diagnosis can lead to inadequate resection of an APGT initially considered to be benign, if using an endoscopic approach. Additionally, primarily due to oncological reasons, the feasibility of endoscopic-assisted surgery of benign APGT is questionable. This opinion is supported by previous studies which reported reduced recurrence rates (less than 4%) associated with extended surgical technique compared to high incidence of recurrence (25-40%) following enucleation of the parotid gland PA.<sup>67-69</sup> Two patients referred to the our institution due to local recurrence after previous treatment of PA using direct transcutaneous approach, also support the importance of adequate tumor resection. The re-operation carries a higher risk of facial nerve injury and local

recurrence which varies from 15 to 30% and 15 to 75%, respectively.<sup>70-73</sup> Moreover, since recurrent tumors of the parotid occurs 3-9 years after initial surgical treatment, short follow-up in cases of endoscopic-assisted resection studies is not a sufficient for recurrence detection and analysis of true recurrence rates.<sup>71,73</sup> Endoscopic-assisted approaches may be considered as an alternative in the treatment of small benign APGT, but larger series with an updated and mature follow-up period are needed in order to utilize its full potential in APGT treatment.

Accessory parotid gland tumors are very rare, but should be considered in the differential diagnosis of a mid-cheek mass. According to our results patients with APGT were younger than other authors reported. Detailed diagnostics and pretreatment work-up are needed in order to avoid misdiagnosis and undertreatment. Approaches through standard parotidectomy and facelift incision are recommended for surgical treatment of APGT, with minimally invasive techniques being reserved for benign subtypes. Although series of malignant APGT are limited, the survival is favorable. Further investigations and large prospective and multicenter trials are needed in order to define optimal extent of surgery as well as adjuvant treatment modalities.

## **Declarations**

***Funding and Conflict of Interests:*** We disclose any commercial associations that might pose a potential, perceived or real conflict of interest. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, donations, advisory board memberships, or payments for conducting or publicizing the study. All authors have viewed and agreed to the submission.

***Ethical Approval:*** The Ethics Board of University Hospital Dubrava has decided that a special ethical approval is not needed because all involved in this study signed written patient consent.

***Acknowledgments:*** none



## References

1. Perzik S White I. Surgical management of preauricular tumors of the accessory parotid apparatus. *Am J Surg.* 1966 Oct;112(4):498-503.
2. Frommer J. The human accessory parotid gland: its incidence, nature, and significance. *Oral Surg Oral Med Oral Pathol.* 1977 May;43(5):671-6.
3. Toh H, Kodama J, Fukuda J, Rittman B, Mackenzie I. Incidence and histology of human accessory parotid glands. *Anat Rec.* 1993 Jul;236(3):586-90.
4. Johnson F, Spiro R. Tumors arising in accessory parotid tissue. *Am J Surg.* 1979 Oct;138(4):576-8.
5. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. *Crit Rev OncolHematol.* 2010 May;74(2):134-48. doi: 10.1016/j.critrevonc.2009.10.004.
6. Xie L, Zhang D, Lu MM, Gao BM. Minimally invasive endoscopic-assisted resection of benign tumors in the accessory parotid gland: 5 case studies. *Head Neck.* 2012 Aug;34(8):1194-7.
7. Li B, Zhang L, Zhao Z, Shen G, Wang X. Minimally invasive endoscopic resection of benign tumours of the accessory parotid gland: an updated approach. *Br J Oral Maxillofac Surg.* 2013 Jun;51(4):342-6.
8. Zhang DM, Wang YY, Liang QX, Song F, Chen WL, Zhang B .Endoscopic-Assisted Resection of Benign Tumors of the Accessory Parotid Gland. *J Oral Maxillofac Surg.* 2015 Aug;73(8):1499-504. doi: 10.1016/j.joms.2015.01.032. Epub 2015 Feb 7.

9. Woo S. Endoscope-assisted transoral accessory parotid mass excision. *Head Neck*. 2016 Jan;38(1):E7-12.
10. Luksic I, Suton P, Rogic M, Dokuzovic S. Accessory parotid gland tumours: 24 years of clinical experience. *Int J Oral Maxillofac Surg*. 2012 Dec;41(12):1453-7.
11. Ma H, Jin S, Du Z, Wang L, Zhang Z, Wang Y. Pathology and management of masses in the accessory parotid gland region: 24-year experience at a single institution. *J Craniomaxillofac Surg*. 2018 Feb;46(2):183-189.
12. Yang X, Ji T, Wang LZ et al. Clinical management of masses arising from the accessory parotid gland. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2011 Sep;112(3):290-7.
13. Klotz DA, Coniglio JU. Prudent management of the mid-cheek mass: revisiting the accessory parotid gland tumor. *Laryngoscope*. 2000 Oct;110(10 Pt 1):1627-32.
14. De Riu G, Meloni SM, Massarelli O, Tullio A. Management of midcheek masses and tumors of the accessory parotid gland. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2011 May;111(5):e5-11.
15. Lin DT, Coppit GL, Burkey BB, Netterville JL. Tumors of the accessory lobe of the parotid gland: a 10-year experience. *Laryngoscope*. 2004 Sep;114(9):1652-5.
16. Choi HJ, Lee YM, Kim JH, Tark MS, Lee JH. Wide excision of accessory parotid gland with anterior approach. *J Craniofac Surg*. 2012 Jan;23(1):165-8.
17. Polayes IM, Rankow RM. Cysts, masses, and tumors of the accessory parotid gland. *Plast Reconstr Surg*. 1979 Jul;64(1):17-23.

18. Dell' AversanaOrabona G, Abbate V, Piombino P, Iaconetta G, Califano L. Midcheek mass: 10 year of clinical experience. *J Craniomaxillofac Surg.* 2014 Oct;42(7):e353-8.
19. Kaneko K, Kanai R. Cavernous hemangioma of the accessory parotid gland. *J Craniofac Surg.* 2011 Nov;22(6):e28-9.
20. Tsegga TM, Britt JD, Ellwanger AR. Pleomorphic adenoma of the accessory parotid gland: case report and reappraisal of intraoral extracapsular dissection for management. *J Oral Maxillofac Surg.* 2015 Mar;73(3):564-70.
21. Schmutzhard J, Schwentner IM, Andrie J, Gunkel AR, Sprinzl GM. Resection of accessory parotid gland tumors through a peroral approach with facial nerve monitoring. *J Craniofac Surg.* 2007 Nov;18(6):1419-21.
22. Newberry TR, Kaufmann CR, Miller FR. Review of accessory parotid gland tumors: pathologic incidence and surgical management. *Am J Otolaryngol.* 2014 Jan-Feb;35(1):48-52.
23. Jung YH, Hah JH, Sung MW, Kim KH. Parotidotomy approach for a midcheek mass: a new surgical strategy. *Laryngoscope.* 2010 Mar;120(3):495-9.
24. Lewkowicz A, Levy Y, Zeltser R, Zagury A, Nahlieli O. Accessory parotid gland masses. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2000 May;89(5):610-2.
25. Osborne RF, Purohit MR, Hamilton JS. Pleomorphic adenoma of the accessory parotid gland. *Ear Nose Throat J.* 2005 May;84(5):274-5.
26. Ramachar SM, Huliappa HA. Accessory parotid gland tumors. *Ann Maxillofac Surg.* 2012 Jan;2(1):90-3.

27. Sun G, Hu Q, Tang E, Yang X, Huang X. Diagnosis and treatment of accessory parotid-gland tumors. *J Oral Maxillofac Surg.* 2009 Jul;67(7):1520-3.
28. Rodino W, Shaha AR. Surgical management of accessory parotid tumors. *J SurgOncol.* 1993 Nov;54(3):153-6.
29. Chang CH, Mun GH, Lim SY, Hyon WS, Bang SI, Oh KS. Cavernous vascular tumor of the accessory parotid gland. *J Craniofac Surg.* 2007 Nov;18(6):1493-6.
30. Kakuki T, Takano K, Kurose M et al. Accessory parotid gland tumors: A series of 4 cases. *Ear Nose Throat J.* 2016 Jul;95(7):E35-8.
31. Das S, Nayak UK, Buggavetti R, Sekhar S. Adenoid Cystic Carcinoma of Accessory Parotid Gland: A Case Report. *J Oral Maxillofac Surg.* 2016 May;74(5):1097.e1-5.
32. Funamura JL, Aouad RK, Ramsamooj R, Donald PJ. Salivary duct carcinoma of the accessory parotid gland. *Otolaryngol Head Neck Surg.* 2013 Aug;149(2):347-8.
33. Al-Hashim MA, Al-Jazan NA. Salivary duct carcinoma of accessory parotid. *J Family Community Med.* 2017 Sep-Dec;24(3):200-202. doi: 10.4103/jfcm.JFCM\_141\_16.
34. Baklacı D, Güngör V, Özcan M, Yılmaz YF, Ünal A, Çolak A. Adenoid cystic carcinoma of the accessory parotid gland. *Kulak BurunBogazIhtisDerg.* 2015;25(5):302-5. doi: 10.5606/kbbihtisas.2015.45467
35. Yang T, Gu Y, Zhang L, Hua Z. Congenital tri-cavernous hemangiomas of the right buccal region, right accessory parotid gland, and masseter muscle region. *J Craniofac Surg.* 2014 Mar;25(2):678-80. doi: 10.1097/SCS.0000000000000501.

36. Iguchi H, Yamada K, Yamane H, Hashimoto S. Epithelioid myoepithelioma of the accessory parotid gland: pathological and magnetic resonance imaging findings. *Case Rep Oncol*. 2014 May 16;7(2):310-5. doi: 10.1159/000363099.
37. Seith AB, Gadodia A, Sharma R, Parshad R. Unilateral parotid agenesis associated with pleomorphic adenoma of ipsilateral accessory parotid gland. *Ear Nose Throat J*. 2013 Jan;92(1):E13-5.
38. Levine P, Fried K, Krevitt LD, Wang B, Wenig BM. Aspiration biopsy of mammary analogue secretory carcinoma of accessory parotid gland: another diagnostic dilemma in matrix-containing tumors of the salivary glands. *DiagnCytopathol*. 2014 Jan;42(1):49-53. doi: 10.1002/dc.22886. Epub 2012 Jul 16.
39. Nakatsuka S, Harada H, Fujiyama H, Takeda K, Kitamura K, Kimura H, Nagano T, Ito M, Asada Y. An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma? *DiagnPathol*. 2011 Dec 7;6:122. doi: 10.1186/1746-1596-6-122.
40. Colella G, Apicella A, Bove P, Rossiello L, Trodella M, Rossiello R. Oncocytic carcinoma of the accessory lobe of the parotid gland. *J Craniofac Surg*. 2010 Nov;21(6):1987-90. doi: 10.1097/SCS.0b013e3181f503d9.
41. Koudounarakis E, Karatzanis A, Nikolaou V, Velegrakis G. Pleomorphic adenoma of the accessory parotid gland misdiagnosed as glomustumour. *JRSM Short Rep*. 2013 Mar; 4(3): 23. doi: 10.1177/2042533313476693

42. Gomes M, Pepe G, Bomanji J, Al-Salihi O, Du Y, Gacinovic S, Ell P. High-grade mucoepidermoid carcinoma of the accessory parotid gland with distant metastases identified by 18F-FDG PET-CT. *Pediatr Blood Cancer*. 2008 Feb;50(2):395-7.
43. Tamiolakis D, Chimona TS, Georgiou G et al. Accessory parotid gland carcinoma ex pleomorphic adenoma. Case study diagnosed by fine needle aspiration. *Stomatologija*. 2009;11(1):37-40.
44. Breeze J, Ramesar K, Williams MD, Howlett DC. Pleomorphic adenoma arising from accessory parotid tissue presenting as dysphonia. *J R Army Med Corps*. 2008 Mar;154(1):57-9.
45. Sreevathsa M. Ramachar, Harsha A. Huliyyappa. Accessory parotid gland tumors. *Ann Maxillofac Surg*. 2012 Jan-Jun; 2(1): 90–93. doi: 10.4103/2231-0746.95334
46. Hamano T, Okami K, Sekine M, Odagiri K, Onuki J, Iida M, Takahashi M. A case of accessory parotid gland tumor. *Tokai J Exp Clin Med*. 2004 Sep;29(3):131-3.
47. Isogai R, Kawada A, Ueno K, Aragane Y, Tezuka T. Myoepithelioma possibly originating from the accessory parotid gland. *Dermatology*. 2004;208(1):74-8.
48. Tamiolakis D, Thomaidis V, Tsamis I, Jivannakis T, Cheva A, Papadopoulos N. Malignant mucoepidermoid tumor arising in the accessory parotid gland: a case report. *Acta Medica (Hradec Kralove)*. 2003;46(2):79-83.
49. Kawashima Y, Kobayashi D, Ishikawa N, Kishimoto S. A case of myoepithelioma arising in an accessory parotid gland. *J Laryngol Otol*. 2002 Jun;116(6):474-6.

50. Yoshihara T, Suzuki S, Nagao K. Mucoepidermoid carcinoma arising in the accessory parotid gland. *Int J Pediatr Otorhinolaryngol*. 1999 Apr 25;48(1):47-52.
51. Quereshy FA, Goldstein JA. Infantile hemangioma of the accessory parotid gland. *J Craniofac Surg*. 1998 Sep;9(5):468-71.
52. Sakurai K, Urade M, Kishimoto H, Takahashi Y, Hozumi S, Yanagisawa T. Primary squamous cell carcinoma of accessory parotid gland duct epithelium: report of a case. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998 Apr;85(4):447-51.
53. Horii A, Honjo Y, Nose M, Ozaki M, Yoshida J. Accessory parotid gland tumor: a case report. *Auris Nasus Larynx*. 1997;24(1):105-10.
54. Kakulas EG, Smith AC, Sormann G. Pleomorphic adenoma of the accessory parotid gland: case report. *J Oral Maxillofac Surg*. 1994 Aug;52(8):867-70.
55. Afify SE, Maynard JD. Tumours of the accessory lobe of the parotid gland. *Postgrad Med J*. 1992 Jun;68(800):461-2.
56. Kronenberg J, Horowitz A, Creter D. Pleomorphic adenoma arising in accessory salivary tissue with constriction of Stensen's duct. *J Laryngol Otol*. 1988 Apr;102(4):382-3.
57. Richards AT, Chait LA, Skudowitz RB. Tumours of accessory parotid glands. Case reports. *S Afr Med J*. 1984 Jun 16;65(24):971-2.
58. Sun S, Wang P, Wang Y, Su W, Wang F, Yang H. Intraductal papilloma arising from the accessory parotid gland: A case report and literature review. *Medicine (Baltimore)*. 2018 May;97(20):e10761. doi: 10.1097/MD.00000000000010761.

59. Iguchi H, Wada T, Matsushita N, Oishi M, Teranishi Y, Yamane H. Evaluation of usefulness of fine-needle aspiration cytology in the diagnosis of tumours of the accessory parotid gland: a preliminary analysis of a case series in Japan. *ActaOtolaryngol*. 2014 Jul;134(7):768-70. doi: 10.3109/00016489.2014.905704. Epub 2014 May 22.
60. Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ. Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg*. 2016 Jan;154(1):9-23. doi: 10.1177/0194599815607841. Epub 2015 Oct 1.
61. Mukunyadzi P. Review of fine-needle aspiration cytology of salivary gland neoplasms, with emphasis on differential diagnosis. *Am J ClinPathol*. 2002 Dec;118 Suppl:S100-15.
62. Friedman ER, Saindane AM. Pitfalls in the staging of cancer of the major salivary gland neoplasms. *Neuroimaging Clin N Am*. 2013 Feb;23(1):107-22.
63. Hughes JH, Volk EE, Wilbur DC; Cytopathology Resource Committee, College of American Pathologists. Pitfalls in salivary gland fine-needle aspiration cytology: lessons from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. *Arch Pathol Lab Med*. 2005 Jan;129(1):26-31.
64. Atula TS, Varpula MJ, Kurki TJ, Klemi PJ, Grénman R. Assessment of cervical lymph node status in head and neck cancer patients: palpation, computed tomography and low field magnetic resonance imaging compared with ultrasound-guided fine-needle aspiration cytology. *Eur J Radiol*. 1997 Sep;25(2):152-61.



65. Atula TS, Grénman R, Varpula MJ, Kurki TJ, Klemi PJ. Palpation, ultrasound, and ultrasound-guided fine-needle aspiration cytology in the assessment of cervical lymph node status in head and neck cancer patients. *Head Neck*. 1996 Nov-Dec;18(6):545-51.
66. Bialek EJ, Jakubowski W, Zajkowski P, Szopinski KT, Osmolski A. US of the major salivary glands: anatomy and spatial relationships, pathologic conditions, and pitfalls. *Radiographics*. 2006 May-Jun;26(3):745-63.
67. Donovan DT, Conley JJ. Capsular significance in parotid tumor surgery: reality and myths of lateral lobectomy. *Laryngoscope*. 1984 Mar;94(3):324-9.
68. Leverstein H, Tiwari RM, Snow GB, van der Wal JE, van der Waal I. The surgical management of recurrent or residual pleomorphic adenomas of the parotid gland. Analysis and results in 40 patients. *Eur Arch Otorhinolaryngol*. 1997;254(7):313-7.
69. Witt RL. The significance of the margin in parotid surgery for pleomorphic adenoma. *Laryngoscope*. 2002 Dec;112(12):2141-54.
70. Wittekindt C, Streubel K, Arnold G, Stennert E, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: analysis of 108 consecutive patients. *Head Neck*. 2007 Sep;29(9):822-8.
71. Glas AS, Vermey A, Hollema H. et al. Surgical treatment of recurrent pleomorphic adenoma of the parotid gland: a clinical analysis of 52 patients. *Head Neck*. 2001 Apr;23(4):311-6.

72. Phillips PP, Olsen KD. Recurrent pleomorphic adenoma of the parotid gland: report of 126 cases and a review of the literature. *Ann OtolRhinolLaryngol.* 1995 Feb;104(2):100-4.
73. Zbären P, Tschumi I, Nuyens M, Stauffer E. Recurrent pleomorphic adenoma of the parotid gland. *Am J Surg.* 2005 Feb;189(2):203-7.

## **Captions to Illustrations**

*Figure 1.* MRI and MSCT scans of patients with APGT. Arrows point to the tumor.

*Figure 2.* Facelift approach skin incision.

*Figure 3.* Intraoperative photograph.

*Figure 4.* Postoperative photograph (14 months after surgery with facelift approach).

*Table 1.* Clinical features of the study group.

*Table 2.* Review of the published cases of APGT.





